Ignite Creation Date:
2025-12-24 @ 11:02 PM
Ignite Modification Date:
2025-12-25 @ 8:32 PM
Study NCT ID:
NCT03442569
Status:
COMPLETED
Last Update Posted:
2025-07-01
First Post:
2018-02-14
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-09
Start Date Type:
ACTUAL
Primary Completion Date:
2020-09-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-02
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-14
First Submit QC Date:
None
Study First Post Date:
2018-02-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-09-28
Results First Submit QC Date:
None
Results First Post Date:
2021-10-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-16
Last Update Post Date:
2025-07-01
Last Update Post Date Type:
ACTUAL